Research Output Journal of Public Health and Medicine 5(3):1-6, 2025

ROJPHM

ISSN ONLINE: 1115-9715
ISSN PRINT: 1115-6147

https://rojournals.org/roj-public-health-and-medicine/

https://doi.org/10.59298/ROJPHM/2025/531600

Epigenetic Alterations in Benign Prostatic Hyperplasia (BPH): From DNA Methylation to Histone Modifications

Mugisha Emmanuel K.

Faculty of Science and Technology Kampala International University Uganda

ABSTRACT

Benign Prostatic Hyperplasia (BPH) is a common age-related condition that results in the enlargement of the prostate gland, leading to symptoms such as frequent urination and urinary retention. While the pathogenesis of BPH has traditionally been linked to hormonal changes, recent studies have uncovered the crucial role of epigenetic alterations in its development. Epigenetic mechanisms such as DNA methylation, histone modifications, and non-coding RNAs regulate gene expression without altering the DNA sequence, influencing key biological processes such as cell growth, differentiation, and apoptosis. This review focuses on the impact of DNA methylation and histone modifications in BPH pathogenesis, with an emphasis on their potential as therapeutic targets. Understanding the molecular underpinnings of BPH at the epigenetic level provides valuable insights into the development of novel diagnostic and therapeutic strategies for this prevalent condition.

Keywords: Benign Prostatic Hyperplasia; Epigenetics; DNA Methylation; Histone Modifications; Prostate Enlargement

INTRODUCTION

Benign Prostatic Hyperplasia (BPH) is a prevalent and significant medical condition among aging men, marked by the non-cancerous enlargement of the prostate gland[1, 2]. This condition often manifests as a range of bothersome lower urinary tract symptoms (LUTS), including urinary frequency, urgency, weak stream, nocturia, and in some cases, complete urinary retention[3, 4]. These symptoms, which tend to worsen with age, significantly impair the quality of life and are often accompanied by a variety of psychological consequences such as stress, anxiety, and depression. With the aging global population, BPH is projected to affect an increasing number of men, making it a growing public health concern[5]. The pathogenesis of BPH is complex and multifactorial, with several factors contributing to its onset and progression. Historically, the primary focus has been on the role of androgens, particularly dihydrotestosterone (DHT), a potent androgen derived from testosterone via the action of the enzyme 5α-reductase. DHT has long been known to stimulate prostate growth and has been implicated in the development of BPH through its effects on prostate tissue[6, 7]. DHT binds to androgen receptors in prostate cells, initiating a cascade of signaling pathways that promote cell proliferation, survival, and the enlargement of the prostate[8]. As a result, androgen deprivation therapies, such as 5α-reductase inhibitors, have been used for decades as first-line treatments for BPH, offering symptomatic relief by reducing DHT levels and slowing prostate growth. However, despite the significant role of androgens in BPH, recent advances in molecular biology have illuminated additional layers of regulation that influence prostate tissue changes. Specifically, emerging research has highlighted the importance of epigenetic mechanisms in the development and progression of BPH. Epigenetics refers to the heritable changes in gene expression or cellular phenotype that do not involve alterations to the underlying DNA sequence[9]. These modifications can occur at the level of DNA, histones, and non-coding RNAs, providing a sophisticated regulatory layer that can modulate gene activity in response to various environmental and physiological stimuli. Epigenetic changes can affect cellular processes such as gene expression, DNA repair, and cell differentiation, which in turn can influence prostate cell function and contribute to the pathogenesis of BPH[10].

One of the most well-studied epigenetic modifications is DNA methylation, which involves the addition of a methyl group to the 5' position of cytosine residues in CpG dinucleotides. DNA methylation can repress gene expression by preventing the binding of transcription factors or by recruiting methyl-binding proteins that

inhibit transcription. Aberrant DNA methylation patterns have been implicated in the development of various diseases, including cancer and BPH[11]. In the prostate, abnormal DNA methylation of genes involved in cell cycle regulation, apoptosis, and androgen signaling has been observed in BPH tissue, suggesting that these changes may contribute to the excessive prostate growth characteristic of the condition. Moreover, DNA methylation changes in response to environmental factors, such as diet, lifestyle, and aging, may further exacerbate the risk of BPH in susceptible individuals[12].

In addition to DNA methylation, histone modifications play a crucial role in regulating gene expression. Histones are proteins that package DNA into a condensed structure called chromatin, and their post-translational modifications can influence the accessibility of DNA to the transcriptional machinery[13]. Common histone modifications include acetylation, methylation, phosphorylation, and ubiquitination, each of which can either activate or repress gene expression depending on the specific modification and its location within the gene. For example, histone acetylation is generally associated with gene activation, as it relaxes the chromatin structure, allowing greater access to transcription factors. Conversely, histone methylation can be either activating or repressive, depending on the specific context[14]. Alterations in histone modifications have been shown to play a role in various diseases, including prostate cancer and BPH. In BPH, changes in histone acetylation and methylation patterns have been linked to the dysregulation of genes involved in cell proliferation, apoptosis, and inflammation. These changes may contribute to the abnormal cellular behavior observed in BPH, promoting the enlargement of prostate tissue and the development of LUTS[15]. Furthermore, the role of non-coding RNAs, including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), has garnered increasing attention in the context of BPH. These non-coding RNAs do not code for proteins but regulate gene expression at the transcriptional and post-transcriptional levels[16]. MiRNAs are small, 20-24 nucleotide long RNAs that bind to messenger RNAs (mRNAs) to prevent their translation or promote their degradation. Several miRNAs have been identified as key regulators of prostate cell function, and their expression levels are often altered in BPH. For instance, miRNAs that target genes involved in cell cycle regulation, apoptosis, and inflammation may play critical roles in the development of BPH by modulating prostate cell behavior[17]. Similarly, lncRNAs, which are longer non-coding RNAs, have been shown to regulate gene expression through various mechanisms, including chromatin remodeling, transcriptional interference, and miRNA sponging. In BPH, the dysregulation of lncRNAs may contribute to the abnormal growth and function of prostate cells. Given the emerging evidence linking epigenetic modifications to BPH, there is a growing interest in understanding how these changes contribute to the disease process and how they might be targeted for therapeutic intervention. The ability to reverse or modulate epigenetic changes holds significant promise for developing novel treatments for BPH, particularly for patients who do not respond adequately to current androgen-based therapies. By exploring the intricate network of DNA methylation, histone modifications, and non-coding RNA regulation, this review aims to provide a comprehensive overview of the epigenetic mechanisms involved in BPH and their potential as therapeutic targets. Through this in-depth analysis, we seek to shed light on the complex molecular landscape of BPH and offer insights into how epigenetic regulation may play a pivotal role in the pathogenesis and progression of this common and debilitating condition.

DNA Methylation in BPH

DNA methylation is a biochemical process in which a methyl group is added to the 5-position of cytosine residues in CpG dinucleotides, an event that can significantly influence gene expression[18]. This modification is crucial for normal cellular functions, including gene regulation, genomic stability, and X-chromosome inactivation. However, when this process is disrupted, it can lead to aberrant gene expression, contributing to the development of various diseases, including cancers and benign prostatic hyperplasia (BPH). In particular, DNA methylation plays a significant role in the development and progression of BPH by altering the expression of genes that control critical cellular processes such as cell proliferation, differentiation, and apoptosis[19]. In the context of BPH, DNA methylation alterations primarily affect the promoter regions of genes responsible for regulating the cell cycle and programmed cell death. One of the most common forms of DNA methylation alteration in BPH is hypermethylation, particularly of tumor suppressor genes like CDKN2A (which encodes p16INK4a) and PTEN (phosphatase and tensin homolog)[20]. Both CDKN2A and PTEN are crucial regulators of the cell cycle and apoptosis. CDKN2A encodes a protein that inhibits cyclin-dependent kinases, preventing uncontrolled cell cycle progression, while PTEN acts as a tumor suppressor by antagonizing the PI3K-AKT signaling pathway, which is often activated in cancerous growths. The methylation-induced silencing of these genes in BPH can result in the loss of control over cell proliferation, leading to an excessive growth of prostate tissue, a characteristic feature of BPH[21].

Another significant aspect of DNA methylation in BPH is the hypomethylation of genes involved in inflammatory processes. For instance, the NF-kB pathway, which is crucial for inflammation and immune response, can be upregulated in BPH due to hypomethylation of associated genes. NF-kB is known to contribute to the inflammatory environment in various tissues, including the prostate, and prolonged inflammation is a

well-established factor in the enlargement of prostate tissue[22]. The activation of inflammatory pathways through DNA hypomethylation may, therefore, exacerbate the progression of BPH by creating a favorable environment for abnormal cell growth and tissue remodeling.

The DNA methylation changes observed in BPH are not solely the result of intrinsic genetic mutations but are also influenced by environmental and lifestyle factors. Studies suggest that factors such as diet, smoking, and exposure to certain chemicals can contribute to alterations in DNA methylation patterns, thus influencing the development and progression of BPH. For example, diets rich in specific nutrients such as folate, which is essential for DNA methylation, may impact the methylation status of critical genes[23]. This underscores the importance of lifestyle interventions as potential strategies for modifying disease risk. By promoting healthier diets and reducing exposure to environmental toxins, it may be possible to mitigate the impact of aberrant DNA methylation on BPH.

Research into DNA methylation biomarkers holds significant promise for improving the early diagnosis, prognosis, and monitoring of BPH. As our understanding of the specific methylation changes associated with BPH deepens, it may become possible to develop diagnostic tools that identify methylation alterations as early indicators of the disease. These biomarkers could also be used to track disease progression and evaluate the effectiveness of therapeutic interventions, offering a more personalized approach to BPH management[24]. In sum, DNA methylation plays a pivotal role in the development of BPH by modulating the expression of genes that regulate cell growth, apoptosis, and inflammation. The identification of specific methylation changes in BPH may not only enhance our understanding of the disease's molecular mechanisms but also provide new opportunities for early diagnosis, risk assessment, and personalized treatment strategies. Moreover, lifestyle changes that influence DNA methylation could offer promising avenues for preventing or slowing the progression of BPH.

Histone Modifications in BPH

Histone modifications refer to the post-translational changes that occur on histone proteins, which form the structural components of chromatin. These modifications, including acetylation, methylation, phosphorylation, and ubiquitination, regulate chromatin structure and gene expression. In the context of BPH, histone modifications play a crucial role in regulating genes involved in prostate cell proliferation, differentiation, and apoptosis[25]. Histone acetylation is often associated with gene activation. Increased acetylation of histones, particularly at the promoter regions of growth factors such as *VEGF* (vascular endothelial growth factor) and *EGF* (epidermal growth factor), has been linked to enhanced cell proliferation and angiogenesis in BPH. On the other hand, histone methylation can either activate or repress gene expression depending on the specific methyl group added and the location of the modification. For example, trimethylation of histone H3 lysine 4 (H3K4me3) is generally associated with gene activation, while trimethylation of histone H3 lysine 27 (H3K27me3) is associated with gene silencing[26]. The balance between acetylation and methylation in the prostate gland is critical for maintaining normal prostate tissue homeostasis. Dysregulation of these modifications can lead to the abnormal growth of prostate cells, contributing to the development and progression of BPH. Targeting histone-modifying enzymes, such as histone deacetylases (HDACs) and histone methyltransferases, may offer promising therapeutic strategies for managing BPH.

Non-Coding RNAs in BPH

In addition to DNA methylation and histone modifications, non-coding RNAs (ncRNAs), particularly microRNAs (miRNAs), have emerged as crucial regulators in the pathogenesis of benign prostatic hyperplasia (BPH). These small RNA molecules, typically 20-24 nucleotides in length, do not encode proteins but instead regulate gene expression at the post-transcriptional level. miRNAs exert their influence by binding to complementary sequences on messenger RNAs (mRNAs), thereby either inhibiting translation or promoting mRNA degradation[27]. Through these mechanisms, miRNAs contribute to the regulation of various cellular processes, including cell differentiation, proliferation, apoptosis, and inflammation—all of which are critical in BPH development[27, 28]. BPH is a common condition characterized by the non-cancerous enlargement of the prostate gland, often leading to urinary symptoms. The pathophysiology of BPH is complex and involves an imbalance between pro-growth and anti-growth signals in prostate cells, leading to the abnormal proliferation and survival of cells within the prostate. Evidence suggests that dysregulation of miRNA expression plays a significant role in driving these pathological changes. For instance, miR-21 has been implicated in promoting cell survival and proliferation in BPH. It targets several tumor suppressor genes, including PTEN (phosphatase and tensin homolog) and PDCD4 (programmed cell death 4), both of which are involved in regulating cell cycle progression and apoptosis[28]. The downregulation of these tumor suppressors by miR-21 results in the enhanced proliferation of prostate cells, a hallmark of BPH. Elevated levels of miR-21 have been observed in both prostate tissues and serum samples of patients with BPH, indicating its potential as a diagnostic biomarker. In addition to miR-21, other miRNAs, such as miR-155 and miR-146a, have been found to play important roles in the inflammatory processes associated with BPH[29]. Chronic inflammation is a significant contributor to the pathogenesis of BPH, as it promotes the recruitment of immune cells and the release of pro-inflammatory

cytokines that stimulate prostate cell proliferation. miR-155 is known to modulate the expression of several genes involved in inflammation, including components of the NF-kB signaling pathway, which regulates immune responses[30]. Overexpression of miR-155 in BPH has been linked to the amplification of inflammatory signaling, thus exacerbating prostate tissue inflammation and contributing to the disease's progression. Similarly, miR-146a is involved in regulating immune responses by targeting genes like TRAF6 (TNF receptor-associated factor 6) and IRAK1 (interleukin-1 receptor-associated kinase 1), which are key mediators of the inflammatory response. In BPH, increased levels of miR-146a may further exacerbate inflammation and promote the development of prostate enlargement by enhancing the activation of inflammatory pathways[31].

The study of non-coding RNAs in BPH is a rapidly expanding area of research, offering valuable insights into the molecular mechanisms underlying the disease. By identifying miRNAs that are differentially expressed in BPH tissues, researchers are uncovering potential biomarkers for early diagnosis and prognosis.[31] Furthermore, the therapeutic targeting of specific miRNAs offers the possibility of novel treatment strategies for BPH. For example, miRNA-based therapies that either inhibit the expression of pro-proliferative miRNAs like miR-21 or restore the function of tumor suppressor miRNAs could potentially halt or reverse the pathological changes seen in BPH. Overall, the involvement of non-coding RNAs, particularly miRNAs, in BPH underscores the complexity of gene regulation in prostate tissue. As our understanding of the molecular landscape of BPH continues to grow, it is likely that ncRNAs will play an increasingly important role in the development of more effective diagnostic and therapeutic approaches for this common prostate condition.

Epigenetic Modulation as a Therapeutic Strategy

Given the significant role of epigenetic alterations in the pathogenesis of BPH, targeting these modifications presents a promising strategy for developing new treatments[32]. DNA methyltransferase inhibitors, histone deacetylase inhibitors, and small molecules that target histone methyltransferases are all potential therapeutic approaches for modulating the epigenetic landscape of BPH. Additionally, the use of miRNA-based therapies to restore normal gene expression patterns offers a novel approach to managing the disease[32]. Current treatment options for BPH, such as alpha-blockers and 5-alpha-reductase inhibitors, focus on modulating hormonal pathways, but these therapies often come with side effects. Epigenetic therapies, which target the molecular mechanisms underlying prostate cell growth and survival, may provide more effective and targeted treatments with fewer side effects. However, further research is needed to better understand the clinical implications of these epigenetic changes and to identify specific biomarkers that can guide therapy.

CONCLUSION

Epigenetic alterations, including DNA methylation and histone modifications, play a crucial role in the development and progression of BPH. These modifications regulate key genes involved in prostate cell proliferation, differentiation, and apoptosis, offering potential therapeutic targets for the disease. Further research into the epigenetic mechanisms underlying BPH will provide valuable insights into its pathogenesis and pave the way for the development of more targeted and effective treatments. Understanding the interplay between epigenetics and other factors such as hormones, inflammation, and genetics will be key to advancing our knowledge of BPH and improving patient outcomes.

Future Directions

Future studies should focus on the development of non-invasive biomarkers based on epigenetic changes to improve the early diagnosis and monitoring of BPH. Additionally, clinical trials evaluating the efficacy of epigenetic-modulating therapies in BPH are necessary to determine their therapeutic potential. Understanding the interactions between various epigenetic modifications and other molecular pathways in prostate cells will enhance the precision of BPH treatments, leading to personalized approaches for managing this prevalent condition.

REFERENCES

1. Ajayi, A., Abraham, K.: Understanding the role of estrogen in the development of benign prostatic hyperplasia. African Journal of Urology. 24, 93–97 (2018). https://doi.org/10.1016/j.afju.2018.01.005
2. Bae, J., Choo, M., Park, J.H., Oh, J.K., Paick, J.-S., Oh, S.-J.: Holmium Laser Enucleation of Prostate for Benign Prostatic Hyperplasia: Seoul National University Hospital Experience. Int Neurourol J. 15, 29 (2011). https://doi.org/10.5213/inj.2011.15.1.29
3. Ibiam, U.A., Uti, D.E., Ejeogo, C.C., Orji, O.U., Aja, P.M., Nwamaka, E.N., Alum, E.U., Chukwu, C., Aloke, C., Itodo, M.O., Agada, S.A., Umoru, G.U., Obeten, U.N., Nwobodo, V.O.G., Nwadum, S.K., Udoudoh, M.P.: Xylopia aethiopica Attenuates Oxidative Stress and Hepatorenal Damage in Testosterone Propionate-Induced Benign Prostatic Hyperplasia in Rats. Journal of Health and Allied Sciences NU. 14, 477–485 (2024). https://doi.org/10.1055/s-0043-1777836
4. Mitsunari, K., Miyata, Y., Matsuo, T., Mukae, Y., Otsubo, A., Harada, J., Kondo, T., Matsuda, T., Ohba, K., Sakai, H.: Pharmacological Effects and Potential Clinical Usefulness of Polyphenols in Benign Prostatic Hyperplasia. Molecules. 26, 450 (2021). https://doi.org/10.3390/molecules26020450

5. Liu, X., Ma, K., Yang, L., Peng, Z., Song, P., Liu, Z., Zhou, J., Yu, Y., Dong, Q.: The relationship between depression and benign prostatic hyperplasia in middle-aged and elderly men in India: a large-scale population study. BMC Public Health. 23, 2152 (2023). https://doi.org/10.1186/s12889-023-17027-2
6. Ng, M., Leslie, S.W., Baradhi, K.M.: Benign Prostatic Hyperplasia. In: StatPearls. StatPearls Publishing, Treasure Island (FL) (2025)
7. Nicholson, T.M., Ricke, W.A.: Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation. 82, 184–199 (2011). https://doi.org/10.1016/j.diff.2011.04.006
8. Madersbacher, S., Sampson, N., Culig, Z.: Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: A Mini-Review. Gerontology. 65, 458–464 (2019). https://doi.org/10.1159/000496289
9. Nicholson, T.M., Ricke, W.A.: Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation. 82, 184–199 (2011). https://doi.org/10.1016/j.diff.2011.04.006
10. Buskin, A., Singh, P., Lorenz, O., Robson, C., Strand, D.W., Heer, R.: A Review of Prostate Organogenesis and a Role for iPSC-Derived Prostate Organoids to Study Prostate Development and Disease. International Journal of Molecular Sciences. 22, 13097 (2021). https://doi.org/10.3390/ijms222313097
11. Moore, L.D., Le, T., Fan, G.: DNA Methylation and Its Basic Function. Neuropsychopharmacol. 38, 23–38 (2013). https://doi.org/10.1038/npp.2012.112
12. Breiling, A., Lyko, F.: Epigenetic regulatory functions of DNA modifications: 5-methylcytosine and beyond. Epigenetics & Chromatin. 8, 24 (2015). https://doi.org/10.1186/s13072-015-0016-6
13. Gagnidze, K., Pfaff, D.W.: Epigenetic Mechanisms: DNA Methylation and Histone Protein Modification. In: Pfaff, D.W., Volkow, N.D., and Rubenstein, J.L. (eds.) Neuroscience in the 21st Century: From Basic to Clinical. pp. 2677–2716. Springer International Publishing, Cham (2022)
14. Liu, R., Wu, J., Guo, H., Yao, W., Li, S., Lu, Y., Jia, Y., Liang, X., Tang, J., Zhang, H.: Post-translational modifications of histones: Mechanisms, biological functions, and therapeutic targets. MedComm (2020). 4, e292 (2023). https://doi.org/10.1002/mco2.292
15. Sugiura, M., Sato, H., Kanesaka, M., Imamura, Y., Sakamoto, S., Ichikawa, T., Kaneda, A.: Epigenetic modifications in prostate cancer. International Journal of Urology. 28, 140–149 (2021). https://doi.org/10.1111/iju.14406
16. Ratti, M., Lampis, A., Ghidini, M., Salati, M., Mirchev, M.B., Valeri, N., Hahne, J.C.: MicroRNAs (miRNAs) and Long Non-Coding RNAs (lncRNAs) as New Tools for Cancer Therapy: First Steps from Bench to Bedside. Target Oncol. 15, 261–278 (2020). https://doi.org/10.1007/s11523-020-00717-x
17. Tu, Z., Xia, H., Yang, L., Zhai, X., Shen, Y., Li, H.: The Roles of microRNA-Long Non-coding RNA-mRNA Networks in the Regulation of Leaf and Flower Development in Liriodendron chinense. Front. Plant Sci. 13, (2022). https://doi.org/10.3389/fpls.2022.816875
18. Moore, L.D., Le, T., Fan, G.: DNA Methylation and Its Basic Function. Neuropsychopharmacol. 38, 23–38 (2013). https://doi.org/10.1038/npp.2012.112
19. Goel, S., Bhatia, V., Biswas, T., Ateeq, B.: Epigenetic reprogramming during prostate cancer progression: A perspective from development. Semin Cancer Biol. 83, 136–151 (2022). https://doi.org/10.1016/j.semcancer.2021.01.009
20. Park, J.Y.: Promoter Hypermethylation in Prostate Cancer. Cancer Control. 17, 245–255 (2010)
21. Yang, M., Park, J.Y.: DNA Methylation in Promoter Region as Biomarkers in Prostate Cancer. Methods Mol Biol. 863, 67–109 (2012). https://doi.org/10.1007/978-1-61779-612-8_5
22. Austin, D.C., Strand, D.W., Love, H.L., Franco, O.E., Jang, A., Grabowska, M.M., Miller, N.L., Hameed, O., Clark, P.E., Fowke, J.H., Matusik, R.J., Jin, R.J., Hayward, S.W.: NF-κB and Androgen Receptor Variant Expression Correlate with Human BPH progression. Prostate. 76, 491–511 (2016). https://doi.org/10.1002/pros.23140
23. Akhatova, A., Jones, C., Coward, K., Yeste, M.: How do lifestyle and environmental factors influence the sperm epigenome? Effects on sperm fertilising ability, embryo development, and offspring health. Clinical Epigenetics. 17, 7 (2025). https://doi.org/10.1186/s13148-025-01815-1
24. Alvarado-Cruz, I., Alegría-Torres, J.A., Montes-Castro, N., Jiménez-Garza, O., Quintanilla-Vega, B.: Environmental Epigenetic Changes, as Risk Factors for the Development of Diseases in Children: A Systematic Review. Annals of Global Health. 84, (2018). https://doi.org/10.29024/aogh.909
25. Ramazi, S., Allahverdi, A., Zahiri, J.: Evaluation of post-translational modifications in histone proteins: A review on histone modification defects in developmental and neurological disorders. J Biosci. 45, 135 (2020)
26. Duan, X., Xing, Z., Qiao, L., Qin, S., Zhao, X., Gong, Y., Li, X.: The role of histone post-translational modifications in cancer and cancer immunity: functions, mechanisms and therapeutic implications. Front. Immunol. 15, (2024). https://doi.org/10.3389/fimmu.2024.1495221

27. Bure, I.V., Nemtsova, M.V., Kuznetsova, E.B.: Histone Modifications and Non-Coding RNAs: Mutual Epigenetic Regulation and Role in Pathogenesis. Int J Mol Sci. 23, 5801 (2022). https://doi.org/10.3390/ijms23105801
28. Prabhakaran, R., Thamarai, R., Sivasamy, S., Dhandayuthapani, S., Batra, J., Kamaraj, C., Karthik, K., Shah, M.A., Mallik, S.: Epigenetic frontiers: miRNAs, long non-coding RNAs and nanomaterials are pioneering to cancer therapy. Epigenetics Chromatin. 17, 31 (2024). https://doi.org/10.1186/s13072-024-00554-6
29. Joković, S.M., Dobrijević, Z., Kotarac, N., Filipović, L., Popović, M., Korać, A., Vuković, I., Savić-Pavićević, D., Brajušković, G.: MiR-375 and miR-21 as Potential Biomarkers of Prostate Cancer: Comparison of Matching Samples of Plasma and Exosomes. Genes (Basel). 13, 2320 (2022). https://doi.org/10.3390/genes13122320
30. Salgado-Hernández, S.V., Martínez-Retamoza, L., Ocadiz-Delgado, R., Pérez-Mora, S., Cedeño-Arboleda, G.E., Gómez-García, M. del C., Gariglio, P., Pérez-Ishiwara, D.G.: miRNAs Dysregulated in Human Papillomavirus-Associated Benign Prostatic Lesions and Prostate Cancer. Cancers. 17, 26 (2025). https://doi.org/10.3390/cancers17010026
31. Saba, R., Sorensen, D.L., Booth, S.A.: MicroRNA-146a: A Dominant, Negative Regulator of the Innate Immune Response. Front Immunol. 5, 578 (2014). https://doi.org/10.3389/fimmu.2014.00578
32. Dobosy, J.R., Roberts, J.L.W., Fu, V.X., Jarrard, D.F.: The Expanding Role of Epigenetics in the Development, Diagnosis and Treatment of Prostate Cancer and Benign Prostatic Hyperplasia. The Journal of Urology. 177, 822–831 (2007). https://doi.org/10.1016/j.juro.2006.10.063

CITE AS: Mugisha Emmanuel K. (2025). Epigenetic Alterations in Benign Prostatic Hyperplasia (BPH): From DNA Methylation to Histone Modifications. Research Output Journal of Public Health and Medicine 5(3):1-6. https://doi.org/10.59298/ROJPHM/2025/531600